Your Article Summary
See Latest ArticlesNovel agents in development for pediatric sarcomas
Current Opinion in Oncology, 06/16/09
Hughes D - Pediatric sarcomas have diverse biology and distinct signaling pathways, making detailed preclinical evaluation of small molecule inhibitors essential to guiding the design of further clinical investigations.
Related Articles
Pediatric osteogenic sarcoma
Current Opinion in Pediatrics, 11/17/09
Relevance Score: 68%
Harmonizing adult and pediatric approaches to the treatment of soft-tissue sarcoma
Expert Review of Anticancer Therapy, 11/12/09
Relevance Score: 67%
FDG PET imaging of childhood sarcomas
Pediatric Blood & Cancer, 11/10/09
Relevance Score: 67%
Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel
Journal of Pediatric Hematology/Oncology, 11/06/09
Relevance Score: 67%
Alveolar soft-part sarcoma of the tongue in a 17-month-old
ENT Journal, 10/19/09
Relevance Score: 67%
Today in Pediatric Heme/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of atypical central neurocytoma in a child with high dose chemotherapy and autologous stem cell rescue
Journal of Neuro-Oncology, 12/04/09
Current Approach to Pediatric Soft Tissue Sarcomas
The Oncologist, 12/03/09
Frequency and prognostic significance of murine double minute protein-2 overexpression and p53 gene mutations in childhood acute lymphoblastic leukemia
Hematology, 12/02/09
Today in Soft Tissue/Sarcoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical management of uterine sarcomas
The Lancet Oncology, 12/04/09
Infantile Fibrosarcoma: Management Based on the European Experience
Journal of Clinical Oncology, 12/04/09
Transformation potential of bone marrow stromal cells into undifferentiated high-grade pleomorphic sarcoma
Journal of Cancer Research & Clinical Oncology, 12/04/09